A detailed history of Gateway Investment Advisers LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Gateway Investment Advisers LLC holds 66,561 shares of VRTX stock, worth $30 Million. This represents 0.34% of its overall portfolio holdings.

Number of Shares
66,561
Previous 67,959 2.06%
Holding current value
$30 Million
Previous $31.9 Million 2.82%
% of portfolio
0.34%
Previous 0.36%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 10, 2024

SELL
$460.0 - $505.78 $643,080 - $707,080
-1,398 Reduced 2.06%
66,561 $31 Million
Q2 2024

Jul 12, 2024

SELL
$392.81 - $485.53 $606,105 - $749,172
-1,543 Reduced 2.22%
67,959 $31.9 Million
Q1 2024

Apr 12, 2024

SELL
$407.69 - $446.08 $1.85 Million - $2.03 Million
-4,542 Reduced 6.13%
69,502 $29.1 Million
Q4 2023

Jan 09, 2024

BUY
$343.0 - $410.68 $746,368 - $893,639
2,176 Added 3.03%
74,044 $30.1 Million
Q3 2023

Oct 19, 2023

SELL
$338.18 - $362.46 $39,228 - $42,045
-116 Reduced 0.16%
71,868 $25 Million
Q2 2023

Jul 13, 2023

BUY
$314.42 - $351.91 $1,886 - $2,111
6 Added 0.01%
71,984 $25.3 Million
Q1 2023

Apr 11, 2023

SELL
$283.23 - $323.1 $67,691 - $77,220
-239 Reduced 0.33%
71,978 $22.7 Million
Q4 2022

Jan 13, 2023

SELL
$285.76 - $321.48 $1.2 Million - $1.35 Million
-4,207 Reduced 5.5%
72,217 $0
Q3 2022

Oct 07, 2022

BUY
$273.83 - $305.53 $1.44 Million - $1.6 Million
5,245 Added 7.37%
76,424 $22.1 Million
Q2 2022

Jul 13, 2022

SELL
$234.96 - $292.55 $3.78 Million - $4.7 Million
-16,074 Reduced 18.42%
71,179 $20.1 Million
Q1 2022

Apr 14, 2022

SELL
$221.42 - $260.97 $596,284 - $702,792
-2,693 Reduced 2.99%
87,253 $22.8 Million
Q4 2021

Jan 14, 2022

SELL
$177.01 - $223.45 $2.2 Million - $2.78 Million
-12,423 Reduced 12.14%
89,946 $19.8 Million
Q3 2021

Oct 22, 2021

SELL
$181.39 - $202.99 $160,348 - $179,443
-884 Reduced 0.86%
102,369 $18.6 Million
Q2 2021

Jul 13, 2021

SELL
$187.49 - $221.1 $2.41 Million - $2.85 Million
-12,869 Reduced 11.08%
103,253 $20.8 Million
Q1 2021

Apr 14, 2021

SELL
$207.02 - $241.31 $539,494 - $628,853
-2,606 Reduced 2.19%
116,122 $25 Million
Q4 2020

Jan 14, 2021

SELL
$207.01 - $276.09 $142,215 - $189,673
-687 Reduced 0.58%
118,728 $28.1 Million
Q3 2020

Oct 19, 2020

SELL
$255.65 - $303.1 $1.49 Million - $1.77 Million
-5,843 Reduced 4.66%
119,415 $32.5 Million
Q2 2020

Jul 15, 2020

SELL
$225.48 - $295.8 $3.37 Million - $4.42 Million
-14,930 Reduced 10.65%
125,258 $36.4 Million
Q1 2020

Apr 13, 2020

SELL
$199.77 - $247.81 $964,889 - $1.2 Million
-4,830 Reduced 3.33%
140,188 $33.4 Million
Q4 2019

Jan 09, 2020

BUY
$166.71 - $223.91 $546,642 - $734,200
3,279 Added 2.31%
145,018 $31.8 Million
Q3 2019

Oct 15, 2019

SELL
$166.23 - $187.09 $1.11 Million - $1.25 Million
-6,705 Reduced 4.52%
141,739 $24 Million
Q2 2019

Jul 17, 2019

SELL
$164.61 - $190.37 $40,494 - $46,831
-246 Reduced 0.17%
148,444 $27.2 Million
Q1 2019

Apr 10, 2019

BUY
$163.73 - $194.7 $127,709 - $151,866
780 Added 0.53%
148,690 $27.4 Million
Q4 2018

Jan 14, 2019

BUY
$151.91 - $192.21 $2.4 Million - $3.04 Million
15,796 Added 11.96%
147,910 $24.5 Million
Q3 2018

Oct 16, 2018

SELL
$167.73 - $192.74 $48,641 - $55,894
-290 Reduced 0.22%
132,114 $25.5 Million
Q2 2018

Jul 11, 2018

SELL
$145.72 - $169.96 $364,445 - $425,069
-2,501 Reduced 1.85%
132,404 $22.5 Million
Q1 2018

Apr 12, 2018

SELL
$151.6 - $177.13 $385,670 - $450,618
-2,544 Reduced 1.85%
134,905 $22 Million
Q4 2017

Jan 17, 2018

SELL
$137.28 - $155.55 $12,492 - $14,155
-91 Reduced 0.07%
137,449 $20.6 Million
Q3 2017

Oct 16, 2017

BUY
$148.13 - $162.24 $20.4 Million - $22.3 Million
137,540
137,540 $20.9 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $116B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Gateway Investment Advisers LLC Portfolio

Follow Gateway Investment Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gateway Investment Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gateway Investment Advisers LLC with notifications on news.